Tag: hereditary angioedema therapeutics global market

  • Hereditary Angioedema Therapeutics Market Growth Potential: Key Insights for 2024-2033

    Hereditary Angioedema Therapeutics Market Growth Potential: Key Insights for 2024-2033

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    How Will the Hereditary Angioedema Therapeutics Market Grow from 2024 to 2033?

    In recent times, the hereditary angioedema therapeutics market has seen a swift enlargement. The market is poised to swell from $5.74 billion in 2023 to $6.76 billion in 2024, reflecting a compound annual growth rate (CAGR) of 17.6%. The growth experienced in the past can be credited to factors such as enhanced diagnosis and awareness, extended access to treatment, the launch of research and development programs, educational efforts and advocacy for patients, as well as regulatory approvals.

    The market size for therapeutics for hereditary angioedema is predicted to significantly increase in the coming years, reaching $13.47 billion in 2028 with a compound annual growth rate (CAGR) of 18.8%. The growth during the forecast period can be ascribed to advancements in targeted therapies, worldwide market expansion, progress in gene therapy, the rising trend of personalized medicine, and collaboration in research and treatment. The key trends projected for the forecast period encompass global access initiatives, health economic outcomes research, early intervention strategies, and pediatric hae therapeutics.

    Claim Your Free Sample of the Global Hereditary Angioedema Therapeutics Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

    What Aspects Are Influencing the Growth Rate of the hereditary angioedema therapeutics Market?

    The progressive upsurge in cases of hereditary angioedema is likely to drive the expansion of the hereditary angioedema market. Hereditary angioedema, a seldom found genetic disease, is typified by periodic episodes of severe swelling on the skin and the mucous membrane. The resultant swelling is due to an excessive pile-up of liquids (EDEMA), manifesting anywhere in the body including hands, feet, face, intestines, and the airways. For instance, in June 2022, the Rare Disease Advisor, a global internet-based health resource establishment, reports that around 1 in every 50,000 individuals globally is afflicted by hereditary angioedema with prevalence data ranging between 1:10,000 to 1:150,000. HAE incidents account for 15,000 to 30,000 ER visits annually in the US. 5.8% of HAE cases have had an average diagnostic period ranging from 0 to 6 months, and an equivalent percentage has had a diagnostic period extending over ten years. Thus, the increasing incidents of hereditary angioedema are driving the hereditary angioedema market’s expansion.

    What Are the Critical Segments of the Hereditary Angioedema Therapeutics Market?

    1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes

    2) By Route of Administration: Intravenous, Subcutaneous, Oral

    3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

    4) By Application: Prophylaxis, On-demand

    What Trends Are Redefining Consumer Expectations in the Hereditary Angioedema Therapeutics Market?

    In the hereditary angioedema therapeutics market, a prominent emerging trend is the development of innovative products by major companies. These companies are combining efforts like ligand-conjugated (LICA) experimental antisense medicine and gene therapy in order to maintain their market stance. For example, in March 2023, the US-based clinical-stage biotechnology firm, Intellia Therapeutics, introduced an Investigational New Drug (IND) NTLA-2002, which is approved by the United States Food and Drug Administration for treating hereditary angioedema. This approval further allows the extension of the ongoing Phase 1/2 trial to the US in its global Phase 2 segment. Post a single-dose therapy, the target gene, kallikrein B1 (KLKB1), gets deactivated, which results in a permanent decrease in plasma kallikrein protein activity and aid in preventing HAE attacks. NTLA-2002 thus emerges as a prospective candidate for in vivo genome editing.

    Order Now for Fast Delivery of Your Hereditary Angioedema Therapeutics Market Report!

    https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

    What Are the Leading Regions in the Hereditary Angioedema Therapeutics Market Expansion?

    North America was the largest region in the global hereditary angioedema therapeutics market in 2023. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

    The Hereditary Angioedema Therapeutics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the hereditary angioedema therapeutics market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Hereditary Angioedema Therapeutics Market Include

    1. Hereditary Angioedema Therapeutics Market Executive Summary

    2. Hereditary Angioedema Therapeutics Market Segments

    3. Hereditary Angioedema Therapeutics Market Size And Template Market Growth Rate

    4. Key Hereditary Angioedema Therapeutics Market Trends

    5. Major Hereditary Angioedema Therapeutics Market Drivers

    ……

    25. Key Mergers And Acquisitions In The Hereditary Angioedema Therapeutics Market

    26. Top Hereditary Angioedema Therapeutics Companies

    27. Hereditary Angioedema Therapeutics Market Opportunities And Strategies

    28. Hereditary Angioedema Therapeutics Market, Conclusions And Recommendations

    29. Appendix

    Discover Related Reports by The Business Research Company:

    Psoriatic Arthritis Treatment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

    Neutropenia Biologic Drug Treatment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/neutropenia-biologic-drug-treatments-global-market-report

    Urinary Stone Treatment Devices And Equipment Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/urinary-stone-treatment-devices-and-equipment-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Hereditary Angioedema Therapeutics Market Forecast 2024: Forecast Market Size, Drivers And Key Segments

    Hereditary Angioedema Therapeutics Market Forecast 2024: Forecast Market Size, Drivers And Key Segments

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    Understanding Market Dynamics

    • The hereditary angioedema therapeutics market has witnessed rapid expansion.
    • From $5.74 billion in 2023 to $6.76 billion in 2024, it’s set to grow at a CAGR of 17.6%.
    • Historic growth credited to improved diagnosis, treatment access, and research.
    • Forecast predicts a surge to $13.47 billion by 2028 at a CAGR of 18.8%.

    Fueling Growth: Surging Prevalence Of Hereditary Angioedema

    • Hereditary angioedema (HAE) is a rare genetic disorder characterized by severe swelling.
    • Global prevalence estimates range from 1:10,000 to 1:150,000.
    • HAE episodes result in significant emergency room visits annually.
    • Diagnosis times vary, with some cases taking over 10 years to diagnose.

    View More On The Hereditary Angioedema Therapeutics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

    Innovative Therapeutic Advancements Shape The Landscape

    • Product innovation drives market trends.
    • Companies focus on ligand-conjugated investigational antisense medicine and gene therapy.
    • Intellia Therapeutics launches NTLA-2002, an investigational antisense medicine for HAE.
    • Takeda Pharmaceutical acquires Nimbus Lakshmi Inc., strengthening its late-stage pipeline.

    Segmentation Insights: Understanding Market Landscape

    • Segmentation by drug class includes C1 esterase inhibitor, selective bradykinin B2 receptor antagonist, and more.
    • Routes of administration encompass intravenous, subcutaneous, and oral.
    • Distribution channels vary from hospital pharmacy to retail pharmacy.
    • Applications include prophylaxis and on-demand treatments.

    Regional Dynamics: North America Leads, Asia-Pacific Emerges

    • North America dominated the market in 2023.
    • Asia-Pacific anticipates rapid growth in the forecast period.

    Conclusion: Navigating Opportunities in HAE Therapeutics
    The hereditary angioedema therapeutics market presents significant growth prospects driven by increasing prevalence and advancements in therapeutic innovations. With a focus on personalized medicine and collaboration, stakeholders can address the unmet needs of patients while expanding their global footprint. As the market evolves, initiatives in research, diagnosis, and treatment access will play pivotal roles in shaping its trajectory. By leveraging emerging trends and fostering strategic partnerships, the hereditary angioedema therapeutics market is poised to offer transformative solutions for patients worldwide.

    Request A Sample Of The Global Hereditary Angioedema Therapeutics Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=10810&type=smp